SCA
BIO icon

Snowden Capital Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Snowden Capital Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-503
Closed -$248K – 1116
2022
Q2 		$248K Sell
503
-117
-19% -$60.9K 0.01% 948
2022
Q1 		$349K Buy
620
+243
+64% +$146K 0.01% 758
2021
Q4 		$284K Sell
377
-166
-31% -$124K 0.01% 581
2021
Q3 		$405K Hold
543
– – 0.02% 594
2021
Q2 		$350K Buy
+543
New +$330K 0.02% 654

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Snowden Capital Advisors's BIO Position: Q3 2022 in Review

Snowden Capital Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2022, closing a stake of 503 shares — an estimated $248K sold.

Snowden Capital Advisors first reported a position in BIO in Q2 2021 and held it in 5 quarters. The position peaked at $405K in Q3 2021. 484 funds tracked by Wall St. Rank hold BIO as of Q3 2022.

  • Snowden Capital Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q3 2022 after selling out during the quarter.
  • Snowden Capital Advisors sold 503 Bio-Rad Laboratories Class A shares in Q3 2022, an estimated $248K.
  • Snowden Capital Advisors first reported a position in Bio-Rad Laboratories Class A in Q2 2021 and held it in 5 quarters.
  • Snowden Capital Advisors's Bio-Rad Laboratories Class A position peaked at $405K in Q3 2021.
  • 484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2022.

Based on Snowden Capital Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.